# Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

> **NCT01058434** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 43 (actual)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** TKI258

## Key facts

- **NCT ID:** NCT01058434
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01058434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01058434, "Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01058434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*